Myelofibrosis Treatments in 2024: Treating this RARE, BLOOD Cancer | The Patient Story

Ruth Fein has been living with an MPN for nearly 30 years. She was first diagnosed with essential thrombocythemia (ET) then polycythemia vera (PV) and was later diagnosed with myelofibrosis. In this discussion, she's joined by top MPN specialist, Dr. Naveen Pemmaraju with MD Anderson.

They give a comprehensive overview of the four FDA-approved JAK inhibitors used to treat myelofibrosis - ruxolitinib, fedratinib, pacritinib, and momelotinib.

They also share exciting developments in clinical trials, including combinations with selinexor, navitoclax, luspatercept, pelabresib, and others. Plus, the role of stem cell transplants, manging anemia and potential treatment side effects.

Full article here ⇢ https://tinyurl.com/4khaks5a

#cancerstories #thepatientstory #myelofibrosis #rarecancer #MPN #cancerresearch #bloodcancer #cancertreatment #myeloproliferativeneoplasms #myeloproliferativeneoplasm #raredisease #bloodcancer #hematology #diagnosis #treatment

Myelofibrosis:
Myelofibrosis is an uncommon type of bone marrow cancer that disrupts your body's normal production of blood cells. It can cause severe scarring in your bone marrow, leading to severe anemia that can cause weakness and fatigue. Myelofibrosis often causes an enlarged spleen.

Myelofibrosis is considered to be a chronic leukemia — a cancer that affects the blood-forming tissues in the body. Myelofibrosis belongs to a group of diseases called myeloproliferative disorders.

The Patient Story:
The Patient Story is led by a dedicated team of medical, editorial, and video experts, committed to authentically portraying the cancer patient experience. Sharing your story holds transformative power, culturally and personally. We handle each narrative with utmost care, compassion, and scientific rigor.

Our editorial process adheres to the highest journalistic standards, ensuring medically researched, vetted, and fact-checked content. Backed by experienced medical professionals, we offer insights into the latest medical advancements.

Beyond patient narratives, we provide comprehensive coverage of cancer news and medical resources. From symptoms to clinical trials, insurance, finances, and support groups, we offer guidance in a humanized manner.

Video Chapters:
00:00 Introduction
01:58 Overview of JAK inhibitors
09:25 Considerations for switching JAK inhibitors
11:30 Combination therapies with JAK inhibitors
13:50 Combination therapy with BCL inhibitors
15:23 Combination therapy with Luspatercept
19:09 Other approaches beyond JAK inhibitors
23:59 Improvements in treating anemia
26:00 Role of stem cell transplant

Join Our Community:
Sign up for our FREE website: https://thepatientstory.com/
Facebook:   / thepatientstory  
Instagram:   / thepatientstory  
Twitter:   / patient_story  
Tik Tok:   / patientstory  

The interview has only been edited for clarity.

* Thank you to GSK and AbbVie for their support of our patient education program!
The Patient Story retains full editorial control over all content.

RARE Blood Cancer Treatments in 2024 | Myelofibrosis | The Patient Story
   • Myelofibrosis Treatments in 2024: Tre...